Head-to-head evidence
Ponesimod vs Tascenso ODT
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline
Ponesimod
Marketed by Vanda Pharmaceuticals
NCT02425644 · Phase 3 · completed
This large, randomized, double-blind trial compared ponesimod head-to-head against an approved active comparator (teriflunomide) using relapse rate, a core clinical measure of multiple sclerosis activity, and ponesimod met its primary endpoint with a statistically significant roughly 30% relative reduction in relapses.
Tascenso ODT
Marketed by Cycle Pharmaceuticals Ltd. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ponesimod's landscape · Tascenso ODT's landscape